TEVA PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
September 23, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a 16 or 15d 16 under the Securities Exchange Act of 1934

For the month of September 2008

Commission File Number ______0-16174

__1__

Teva Pharmaceutical Industries Limited				
(Translation of registrant's name into English)				
5 Basel Street, P.O. Box 3190				
Petach Tikva 49131 Israel				
(Address of principal executive offices)				
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F				
Form 20-F Form 40-F				
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule				
101(b)(1):				
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):				
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby				
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934				
Yes NoX				
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):				
82				

www.tevapharm.com

Contact:	Elana Holzman	Teva Pharmaceutical Industries Ltd.	972 (3) 926-7554
----------	---------------	-------------------------------------	------------------

Kevin Mannix Teva North America (215) 591-8912

For Immediate Release

WEBCAST ALERT -FOR IMMEDIATE RELEASE

TEVA TO PRESENT AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE

Jerusalem, Israel, September 23, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the UBS Global Life Sciences Conference in New York.

Eyal Desheh, Chief Financial Officer, will present on September 24, 2008.

What: Teva Presentation at the UBS Global Life Sciences Conference in New York

Who: Eyal Desheh, Chief Financial Officer

When: Wednesday, September 24, 2008 at 3:00 p.m. ET

Where: www.tevapharm.com or

http://events.streamx.us/US/event/eventdetails.aspx?id=ubs20080922

How: Live over the Internet log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.							
About Teva							
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and market generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.							
Teva Pharmaceutical Industries Ltd. Web Site: <u>www.tevapharm.com</u>							

SIGNATURES

Pursuant to the requirements of the Securities Exchan	ge Act of 1934, the re	egistrant has duly c	aused this report to be
signed on its behalf by the undersigned, thereunto dul	authorized.		

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: <u>/s/ Eyal Desheh</u>

Name: Eyal Desheh

Title: Chief Financial Officer

Date: September 23, 2008

__2__